$591 | SAVE $104 | Single User
$1186 | SAVE $209 | Global License

Physician Views: As off-label Avastin use threatens to increase in Europe, where next for wet AMD therapies?
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 16 Jul 2014 | 138 | In Stock
Related Topics: Fovista , Novartis , Roche

Introduction

Scope



The market for wet age-related macular degeneration (AMD) therapies retains significant commercial opportunity, but also notable controversy.


The former is illustrated by the newest market entrant in this space – Regeneron Pharmaceuticals and Bayer's Eylea – which rapidly assumed blockbuster status just a year after launch. The latter is focused primarily on the widespread use of compounded Avastin (Roche's cancer product) in an off-label capacity as a much cheaper alternative to Roche and Novartis' market-leading AMD therapy Lucentis. Long established as a method to treat patients in the US, Italy and France have both recently approved use of off-label Avastin, suggesting that this practice could gain prominence in the EU.


The success of Eylea has demonstrated, however, that innovation still provides the opportunity to trump the much reduced cost of compounded Avastin (Regeneron's product is dosed less frequently than Avastin or Lucentis) and a number of AMD therapies that have moved into late-stage testing are among the most interesting in the industry pipeline.


These include Allergan's DARPin – which appears to be comparable, if not slightly superior, to Lucentis, but with a potential dosing frequency of once every three months (based on Phase II data) – and the combination of Ophthotech's Fovista – which combined with Lucentis demonstrated a statistically significant improvement over Lucentis monotherapy (again, based on Phase II data). See - ViewPoints: Novartis eyeing up longer-term access to US AMD market with licensing deal?


Furthermore, Lucentis has seen its growth rate reinvigorated by approval in the diabetic macular oedema (DME) setting, with progression of Eylea into this indication a potential key catalyst for future growth.


Puchase Reasons


As the wet AMD market continues to evolve rapidly, FirstWord is this week polling US and EU5-based ophthalmologists and asking them...


  • How comfortable they are/would you be prescribing compounded Avastin as an alternative wet age-related macular degeneration (AMD) therapy to Lucentis or Eylea?


  • Which available wet AMD therapy has the strongest overall profile?

  • Based on their experience of the product in AMD, to what percentage of DME patients would you expect to prescribe Eylea 12 months after approval in this indication?

  • Assuming that similar data were provided in Phase III studies for Allergan's DARPin with once-every three months dosing, to what percentage of wet AMD patients they would expect to prescribe the product?

  • Assuming the combination of Ophthotech's anti-PDGF therapy Fovista and Lucentis replicated the statistically superior Phase II
  • performance it demonstrated versus Lucentis in Phase III studies, to what percentage of AMD patients they would expect to prescribe the combination?

    Table of Contents
    for Physician Views: As off-label Avastin use threatens to increase in Europe, where next for wet AMD therapies? [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    138 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    SAVE 15% today! Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: As off-label Avastin use threatens to increase in Europe, where next for wet AMD therapies? [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...